2.0 Receptors Flashcards
1
Q
Adenosine
A
- <b>Class</b> = NANC transmitter<br></br>- <b>Target</b> = A1, A2A, A2B, A3 receptors<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Injected to treat supra ventricular dysrhythmias<br></br>A1 recetor inhibits renin release
2
Q
Atropine
A
- <b>Class</b> =<br></br>- <b>Target</b> = muscarininc ACh receptor<br></br>- <b>Mechanism</b> = Non-selective antagonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Used to be used to induce pupil dilation (but too long lasting, thus now sympathetic agonists used instead)
3
Q
B K 8644
A
- <b>Class</b> = Dihydropryridine<br></br>- <b>Target</b> = L-type voltage gated Ca²⁺ channel<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>:<br></br>Favours mode 2 of channel opening <br></br>- <b>Info</b>:<br></br>Same binding site as nifedipine<br></br>Only used experimentally
4
Q
Benzylcholine mustard
A
- <b>Class</b> = Modified form of ACh<br></br>- <b>Target</b> = Muscarinic AChR<br></br>- <b>Mechanism</b> = Irreversible antagonism<br></br>- <b>Steps</b>: <br></br>1) Irreversibly alkylates muscarinic receptor<br></br>- <b>Info</b>: <br></br>Functions in a time dependent manner → progressive blockade of muscarinic receptors
5
Q
Benzocaine
A
- <b>Class</b> = Local anaesthetic<br></br>- <b>Target</b> = Na⁺ channel<br></br>- <b>Mechanism</b> = Blocker<br></br>- <b>Steps</b>: <br></br>1) Non charged, therefore enters the cell using hydrophobic pathway<br></br>2) <b>Not</b> use-dependent<br></br>3) Not affected by pH<br></br>- <b>Info</b>:
6
Q
alpha-Bungarotoxin
A
- <b>Class</b> = Toxin<br></br>- <b>Target</b> = nAChR at NMJ<br></br>- <b>Mechanism</b> = Irreversible antagonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Produced by branded krait snake
7
Q
Cholera toxin
A
- <b>Class</b> = Toxin<br></br>- <b>Target</b> = Gαs subunit of G protein<br></br>- <b>Mechanism</b> = Causes increased activation of adenylyl cyclase<br></br>- <b>Steps</b>: <br></br>1) Causes ADP-ribosylation of αs<br></br>2) This inhibits GTPase activity → sustained activation of adenylyl cyclase<br></br>- <b>Info</b>:
8
Q
Diltiazem
A
- <b>Class</b> = Benzothiazipine<br></br>- <b>Target</b> = L-type voltage gated Ca²⁺ channel<br></br>- <b>Mechanism</b> = Antagonist<br></br>- <b>Steps</b>: <br></br>Act on different sites than DHPs<br></br>Show use dependence<br></br>Preferentially targets cardiac tissue (because Ca²⁺ channels here have highest opening frequency)<br></br>- <b>Info</b>:<br></br>Ditliazem → ↑ DHP binding
9
Q
d-Tubocurarine
A
- <b>Class</b> =<br></br>- <b>Target</b> = nAChR<br></br>- <b>Mechanism</b> = Antagonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Non selective between ganglionic and NMJ<br></br>Generated by purification of curare<br></br>Charged therefore not orally active
10
Q
Ethinylestradiol
A
- <b>Class</b> = Steroid<br></br>- <b>Target</b> = Estrogen receptor<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Used in contraception<br></br>Estrogen receptor = exception to steroid receptors as it is found in nucleus unbound to ligand
11
Q
Glibenclamide
A
- <b>Class</b> = Sulphonylurea<br></br>- <b>Target</b> = Sulphonylurea receptor (SUR)<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>Binds to SUR → closure of K⁺-ATP channel → depolarisation of panreatic β cells → opening of voltage gated Ca²⁺ channel → insulin release (exocytosis)<br></br>- <b>Info</b>:<br></br>Used in Type II DM
12
Q
Isoprenaline
A
- <b>Class</b> = β agonist<br></br>- <b>Target</b> = β₁ + β₂<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>β₁ → ↑ heart rate<br></br>β₂ → bronchodilation<br></br>- <b>Info</b>:<br></br>Used to be used for asthma - now stopped because caused tachycardia
13
Q
Lidocaine/lignocaine
A
- <b>Class</b> = Local anaesthetic (tertiary amine)<br></br>- <b>Target</b> = Na⁺ channel<br></br>- <b>Mechanism</b> = Blocker<br></br>- <b>Steps</b>: <br></br>1) Binds to and stabilises the inactive conformation of the channel<br></br>2) Crosses membrane in uncharged form<br></br>3) Blocks channel in charged form<br></br>4) Shows use dependence + voltage dependence<br></br>- <b>Info</b>:<br></br>Used as LA but also as antidysrhythmic (ventricular problems)<br></br>Selectivity for smaller and slower conducting fibres (Aδ + C)<br></br>Fast in-fast out kinetics (more effective at high rates of stimulation)
14
Q
Minoxidil
A
- <b>Class</b> = K⁺ channel opener<br></br>- <b>Target</b> = ? K-ATP channel?<br></br>- <b>Mechanism</b> = Opener<br></br>- <b>Steps</b>: <br></br>Exact mechanism unknown<br></br>Opens K⁺ channel → K⁺ efflux → hyperpolarisation → relaxation of smooth muscle (e.g. that surrounding vasculature)<br></br>- <b>Info</b>:<br></br>Used in male baldness, hypertension, asthma, IBS<br></br>- <b>side effect</b>:<br></br>May cause hyperglycaemia by limiting insulin secretion by pancreatic β cells
15
Q
Nicorandil
A
- <b>Class</b> = K⁺ channel opener<br></br>- <b>Target</b> = ? K-ATP channel?<br></br>- <b>Mechanism</b> = Opener<br></br>- <b>Steps</b>: <br></br>Exact mechanism unknown<br></br>Opens K⁺ channel → K⁺ efflux → hyperpolarisation → relaxation of smooth muscle (e.g. that surrounding vasculature)<br></br>- <b>Info</b>:<br></br>Used in HTN and angina (causes ischaemic preconditioning)<br></br>Also an NO donor<br></br>- <b>side effect</b>:<br></br>May cause hyperglycaemia by limiting insulin secretion by pancreatic β cells
16
Q
Nifedipine
A
- <b>Class</b> = Dihydropryridine<br></br>- <b>Target</b> = L-type voltage gated Ca²⁺ channel<br></br>- <b>Mechanism</b> = Antagonist<br></br>- <b>Steps</b>:<br></br>Favours mode 0 of channel opening (inactive state)<br></br>Preferentially stabilises inactive channel, thus favours tissues which are constitutively depolarised (e.g. <b>vascular smooth muscle</b>)<br></br>Use dependence <br></br>- <b>Info</b>:<br></br>Same binding site as Bay K 8644<br></br>Used for HTN and angina<br></br><b>Reduces aldosterone secretion</b>
17
Q
Norethisterone
A
- <b>Class</b> = Steroid<br></br>- <b>Target</b> = Progesterone (progestagen) receptor<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Used in contraception
18
Q
Pertussis toxin
A
- <b>Class</b> = Toxin<br></br>- <b>Target</b> = Gαi subunit of G protein<br></br>- <b>Mechanism</b> = Causes increased activation of adenylyl cyclase<br></br>- <b>Steps</b>: <br></br>1) Causes ADP-ribosylation of αi<br></br>2) This prevents GDP→GTP exchange<br></br>3) Prevents activation of Gαi → ↑ PKA activity<br></br>- <b>Info</b>:<br></br>↑ PKA activity → loss of water through intestine → severe dehydration
19
Q
Prednisolone
A
- <b>Class</b> = Steroid<br></br>- <b>Target</b> = glucocorticoid receptor<br></br>- <b>Mechanism</b> = Agonist<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Used for inflammatory/autoimmune conditions<br></br>Has a lymphocytic effect (useful against leukaemias)<br></br>Administered as prodrug <b>prednisone</b> (converted to prednisolone in liver)
20
Q
Quinidine
A
- <b>Class</b> = Local anaesthetic<br></br>- <b>Target</b> = Na⁺ channel<br></br>- <b>Mechanism</b> = Blocker<br></br>- <b>Steps</b>: <br></br>1) Shows use dependence<br></br>2) Slow in-slow out kinetics therefore shows use dependence at lower rates of stimulation<br></br>- <b>Info</b>:<br></br>Also used as antidysrythmic (Class 1A)
21
Q
Spironolactone
A
- <b>Class</b> = K⁺ sparing diuretic<br></br>- <b>Target</b> = Aldosterone (mineralocorticoid) receptor<br></br>- <b>Mechanism</b> = Antagonist<br></br>- <b>Steps</b>: <br></br>Spironolactone is metabolised to canrenone in the liver<br></br>Canrenone and its K+ salt (potassium canrenone) work as K+ sparing diuretics<br></br>Spironolactone/canrenone compete with aldosterone binding site on cytoplasmic receptor<br></br>Antagonism → ↓ expression of Na⁺/K⁺ ATPase and ENaC → ↓ Na⁺ reabsorption<br></br>- <b>Info</b>:<br></br>Acts on distal tubule<br></br>Rate of onset of diuresis is slow
22
Q
Tamoxifen
A
- <b>Class</b> = Estrogen antagonist<br></br>- <b>Target</b> = Estrogen receptor<br></br>- <b>Mechanism</b> = Competitive antagonist<br></br>- <b>Steps</b>: <br></br>Has lower affinity than oestrogen. Reduces the transcription of estrogen response genes.<br></br>- <b>Info</b>:<br></br>Used for breast cancer<br></br><b>Can have agonist effects in bone and uterus</b>
23
Q
Tetradotoxin
A
- <b>Class</b> = Toxin (guanidium)<br></br>- <b>Target</b> = Na⁺ channel<br></br>- <b>Mechanism</b> = Blocker<br></br>- <b>Steps</b>: <br></br>Contains <b>guanidium group</b><br></br>Blocks Na⁺ channel from outside<br></br>No use-dependence <br></br>- <b>Info</b>:<br></br>Puffer fish<br></br>Does not affect cardiac channels because of the presence of cysteine residues in the cardiac Na⁺ isoform
24
Q
Tyrphostins
A
- <b>Class</b> = RTK inhibitors<br></br>- <b>Target</b> = Receptor tyrosine kinase<br></br>- <b>Mechanism</b> = Inhibition<br></br>- <b>Steps</b>: <br></br>- <b>Info</b>:<br></br>Potential use in the treatment of neoplasms by blocking RTKs implicated in cellular proliferation.<br></br>Example = Glivec for treating CML
25
Q
Verapamil
A
- <b>Class</b> = Phenylalkylamine<br></br>- <b>Target</b> = L-type voltage gated Ca²⁺ channel<br></br>- <b>Mechanism</b> = Antagonist<br></br>- <b>Steps</b>: <br></br>Act on different sites than DHPs<br></br>Show use dependence<br></br>Preferentially targets cardiac tissue (because Ca²⁺ channels here have highest opening frequency)<br></br>- <b>Info</b>:<br></br>Verapamil→ ↓ DHP binding